Patent landscape of pediatric-friendly oral dosage forms and administration devices [0.03%]
儿童友好型口服剂型及给药装置专利景观分析
Christina Karavasili,Angelos Gkaragkounis,Dimitrios G Fatouros
Christina Karavasili
Introduction: The current availability of dosage forms designed specifically for children is limited, constituting common practice the use of unlicensed or off-labeled medicines and extemporaneous preparations. Swallowing...
Coronavirus helicases: attractive and unique targets of antiviral drug-development and therapeutic patents [0.03%]
新型冠状病毒解旋酶：具有吸引力和独特性的抗病毒药物研发及治疗专利靶点
Austin N Spratt,Fabio Gallazzi,Thomas P Quinn et al.
Austin N Spratt et al.
Introduction: Coronaviruses encode a helicase that is essential for viral replication and represents an excellent antiviral target. However, only a few coronavirus helicase inhibitors have been patented. These patents include drug-like comp...
Xue-Li Jing,Shi-Wu Chen
Xue-Li Jing
Introduction: Aurora kinases are a family of serine/threonine kinases, and promote mitotic spindle assembly by regulating centrosome duplication and separation. Aurora kinases are overexpressed in a variety of tumor cell lines, thus, the us...
Phosphoglycerate dehydrogenase (PHGDH) inhibitors: a comprehensive review 2015-2020 [0.03%]
磷酸甘油酸脱氢酶(PHGDH)抑制剂的全面综述(2015-2020)
Quentin Spillier,Raphaël Frédérick
Quentin Spillier
Introduction:The phosphoglycerate dehydrogenase (PHGDH), a metabolic enzyme involved in the serine synthetic pathway (SSP), appears to play a central role in supporting cancer growth and proliferation. PHGDH is a dehydrogenase whose express...
Tankyrase inhibitors as antitumor agents: a patent update (2013 - 2020) [0.03%]
端基核苷酸重复序列酶抑制剂作为抗肿瘤药物的专利更新（2013-2020）
Chirag C Mehta,Hardik G Bhatt
Chirag C Mehta
Introduction: Tankyrase inhibitors gained significant attention as therapeutic targets in oncology because of their potency. Their primary role in inhibiting the Wnt signaling pathway makes them an important class of comp...
Recent development in the discovery of PARP inhibitors as anticancer agents: a patent update (2016-2020) [0.03%]
2016-2020年抗肿瘤PARP抑制剂专利现状及近期研发进展
Uday Kiran Velagapudi,Bhargav A Patel,Xuwei Shao et al.
Uday Kiran Velagapudi et al.
Introduction: Discovery of small molecules that impede the activity of single-strand DNA repair enzyme, PARP1, has led to four marketed drugs for the treatment of advanced-stage cancers. Hence, there is a renewed enthusia...
Novel ligands and modulators of triggering receptor expressed on myeloid cells receptor family: 2015-2020 updates [0.03%]
新发现的髓系细胞表达的触发受体家族配体和调节剂：2015-2020年更新
Harbinder Singh,Vikrant Rai,Sunil K Nooti et al.
Harbinder Singh et al.
Introduction: Triggering receptors expressed on myeloid cells (TREMs) are inflammatory amplifiers with defined pathophysiological role in various infectious diseases, acute and chronic aseptic inflammations, and a variety of cancers, depict...
Novel matrix metalloproteinase inhibitors: an updated patent review (2014 - 2020) [0.03%]
新型基质金属蛋白酶抑制剂专利回顾（2014-2020）
Elena Lenci,Lucrezia Cosottini,Andrea Trabocchi
Elena Lenci
Introduction: Matrix MetalloProteinases (MMPs) are key enzymes in several pathophysiological processes connected to the extracellular matrix (ECM) degradation. Earlier clinical trials evaluating broad spectrum MMP inhibitors as cancer thera...
SARS-CoV-2 RNA-dependent RNA polymerase as a therapeutic target for COVID-19 [0.03%]
以SARS-CoV-2依赖RNA的RNA聚合酶作为治疗COVID-19的靶点
Ilaria Vicenti,Maurizio Zazzi,Francesco Saladini
Ilaria Vicenti
Introduction: The current SARS-CoV-2 pandemic urgently demands for both prevention and treatment strategies. RNA-dependent RNA-polymerase (RdRp), which has no counterpart in human cells, is an excellent target for drug development. Given th...
Asier Selas,Endika Martin-Encinas,Maria Fuertes et al.
Asier Selas et al.
Introduction: Topoisomerases are important targets for therapeutic improvement in the treatment of some diseases, including cancer. Inhibitors and poisons of topoisomerase I can limit the activity of this enzyme in its en...